Beijing Konruns Pharmaceutical Launches Phase III Study for KC1036 in Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd (SHA: 603590), based in Beijing, has received approval from China’s...
Lee’s Pharmaceutical Secures NMPA Approval for Adasuve, Pioneering Loxapine Inhaler for Agitation
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has secured marketing approval from China’s National Medical Products...
AK Medical Holdings Receives NMPA Approval for Hip Surgery Navigation System iBot
AK Medical Holdings Ltd (HKG: 1789), a Chinese medical technology company, has announced that it...
Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus
Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...
Mabwell Bioscience Enters Thai Market with Licensing Deal with Innobic
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a Chinese biopharmaceutical company, has announced the signing...
Taihe Weiye Biotechnology Secures RMB 300 Million in Series A+ Financing to Expand Production
Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has...
Dupixent Trial Success Reinforces Potential in Moderate-to-Severe COPD Treatment
Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have announced that a late-stage replicate trial...
AbbVie’s Epcoritamab Earns EMA Review and FDA Breakthrough Designation for Follicular Lymphoma
AbbVie’s (NYSE: ABBV) bispecific antibody (BsAb) Tepkinly/Epkinly (epcoritamab) has been accepted for review by the...
AstraZeneca to Open R&D Center in Hong Kong, Focusing on Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has concluded a roughly 12-month discussion period with...
Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure
German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance...
Everest Medicines’ Nefecon for IgAN Receives NMPA Approval in China
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that its New Drug Application...
Beijing QL Biopharmaceutical Boosts Pipeline with RMB 200 Million Series B+ Round
Beijing QL Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company, has reportedly secured nearly RMB 200...
Henlius Biotech Gets FDA Clearance for Clinical Study of PD-L1 Targeting ADC HLX43
Shanghai Henlius Biotech Inc. (HKG: 2696), a Chinese biopharmaceutical company, has received approval from the...
CSPC Pharmaceutical Gets NMPA Green Light for SYH2038 Solid Tumor Study
CSPC Pharmaceutical Group Ltd (HKG: 1093), a Chinese pharmaceutical company, has announced that it has...
Abbisko Therapeutics Launches Phase II Trial for Pimocitinib in Advanced Pancreatic Cancer
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced the initiation of...
Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy
Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive...
Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study
Jenscare Scientific Co., Ltd. (HKG: 9877), a Ningbo-based manufacturer of devices for structural heart disease,...
XtalPi Partners with University of Hong Kong’s ABIC to Advance Biomedical Technology Commercialization
XtalPi (QuantumPharm, HKG: 2228) a Sino-U.S. artificial intelligence firm, has signed a memorandum of understanding...
Coherus Biosciences Sets Price for PD-1 Inhibitor Loqtorzi at $8,892.03, Offering 20% Discount Compared to Keytruda
Coherus Biosciences Inc. (NASDAQ: CHRS) announced yesterday in an SEC filing the wholesale price for...
China’s NHSA Issues Guidelines to Strengthen Medical Pricing and Procurement Credit Ratings
The National Healthcare Security Administration (NHSA) has issued a notification concerning medical pricing and tendering...